New Kyowa Hakko Kirin President Steeped In Antibody Drug Research
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin’s new president is considered an expert researcher of antibodies, reflecting the drug maker’s market focus.
Kyowa Hakko Kirin’s new president is considered an expert researcher of antibodies, reflecting the drug maker’s market focus. Nobuo Hanai, a director and senior executive officer of the firm, was chosen by President Yuzuru Matsuda as his successor as president effective March 22. Matsuda is to continue as a company advisor. Hanai is credited with making Kyowa Hakko Kogyo a leader in antibody therapy. (Click here for more – a subscription may be required)
“Antibody Drug Expert Chosen To Lead Kyowa Hakko Kirin” – Nikkei (Japan) (2/1/12)